Abstract
Fetal growth restriction (FGR) is associated with an increased incidence of fetal and neonatal death, and of neonatal morbidity. Babies born following FGR also are at risk of a range of postnatal complications, which may contribute to an increased incidence of disease later in life. There currently are no effective clinical interventions which improve perinatal survival, intrauterine growth and later outcomes of the FGR baby. Postnatal interventions aimed at promoting or accelerating growth in FGR babies to improve outcome, particularly neurodevelopmental outcomes, may further increase the risk of metabolic dysregulation and, therefore, the risk of developing chronic disease in adulthood. An intrauterine intervention to improve nutrition and growth in the FGR fetus may have the potential to decrease mortality and improve long-term outcomes by delaying preterm delivery and mitigating the need for and risks of accelerated postnatal growth.
Keywords: Fetal therapies, growth and development, growth hormone, infant, insulin-like growth factor-I, placenta, preterm, developmental origins of health and disease.
Graphical Abstract
Current Pediatric Reviews
Title:Intrauterine Intervention for the Treatment of Fetal Growth Restriction
Volume: 12 Issue: 3
Author(s): A-M. Spiroski, M. H. Oliver, J. E. Harding and F. H. Bloomfield
Affiliation:
Keywords: Fetal therapies, growth and development, growth hormone, infant, insulin-like growth factor-I, placenta, preterm, developmental origins of health and disease.
Abstract: Fetal growth restriction (FGR) is associated with an increased incidence of fetal and neonatal death, and of neonatal morbidity. Babies born following FGR also are at risk of a range of postnatal complications, which may contribute to an increased incidence of disease later in life. There currently are no effective clinical interventions which improve perinatal survival, intrauterine growth and later outcomes of the FGR baby. Postnatal interventions aimed at promoting or accelerating growth in FGR babies to improve outcome, particularly neurodevelopmental outcomes, may further increase the risk of metabolic dysregulation and, therefore, the risk of developing chronic disease in adulthood. An intrauterine intervention to improve nutrition and growth in the FGR fetus may have the potential to decrease mortality and improve long-term outcomes by delaying preterm delivery and mitigating the need for and risks of accelerated postnatal growth.
Export Options
About this article
Cite this article as:
Spiroski A-M., Oliver H. M., Harding E. J. and Bloomfield H. F., Intrauterine Intervention for the Treatment of Fetal Growth Restriction, Current Pediatric Reviews 2016; 12 (3) . https://dx.doi.org/10.2174/1573396312666160808151856
DOI https://dx.doi.org/10.2174/1573396312666160808151856 |
Print ISSN 1573-3963 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6336 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Induction of Quinone Reductase NQO1 by Resveratrol in Human K562 Cells Involves the Antioxidant Response Element ARE and is Accompanied by Nuclear Translocation of Transcription Factor Nrf2
Medicinal Chemistry Hyperfibrinogenemia is Significantly Associated with an Increased Risk of In-hospital Mortality in Acute Ischemic Stroke Patients
Current Neurovascular Research Human Embryonic and Induced Pluripotent Stem Cells in Cardiovascular Drug Discovery: Patents and Patented Uses
Recent Patents on Cardiovascular Drug Discovery Autologous Mesenchymal Stem Cell Therapy in Progressive Multiple Sclerosis: An Open Label Study
Current Stem Cell Research & Therapy Psychological Stress in Pathogenesis of Essential Hypertension
Current Hypertension Reviews Pain-Relief Medication and Risk of Fractures
Current Drug Safety Could Better Phenotyping Small Vessel Disease Provide New Insights into Alzheimer Disease and Improve Clinical Trial Outcomes?
Current Alzheimer Research Triiodothyronine (T3) Effects on Cardiovascular System in Patients with Heart Failure
Recent Patents on Cardiovascular Drug Discovery Obstructive Sleep Apnoea Syndrome and Diabetes. Fortuitous Association or Interaction?
Current Diabetes Reviews Ethiopathogenesis, Diagnosis and Prevention of Vascular Calcification in End Stage Renal Disease
Current Medicinal Chemistry - Cardiovascular & Hematological Agents Ascorbic Acid and Gene Expression: Another Example of Regulation of Gene Expression by Small Molecules?
Current Genomics MicroRNA-208a Potentiates Angiotensin II-triggered Cardiac Myoblasts Apoptosis via Inhibiting Nemo-like Kinase (NLK)
Current Pharmaceutical Design Benefits of SGLT2 Inhibitors Beyond Glycemic Control – A Focus on Metabolic, Cardiovascular and Renal Outcomes
Current Diabetes Reviews Inflammatory Biomarkers and Cardiovascular Risk Assessment. Current Knowledge and Future Perspectives
Current Pharmaceutical Design Enhanced Proinflammatory State and Autoimmune Activation: a Breakthrough to Understanding Chronic Diseases
Current Pharmaceutical Design Progress in Therapies for Myocardial Ischemia Reperfusion Injury
Current Drug Targets Patenting of Nanopharmaceuticals in Drug Delivery: No Small Issue
Recent Patents on Drug Delivery & Formulation Cardiovascular Disease: A Target for the Pharmacological Effects of Quercetin
Current Topics in Medicinal Chemistry Genetic Basis, Nutritional Challenges and Adaptive Responses in the Prenatal Origin of Obesity and Type-2 Diabetes
Current Diabetes Reviews A New Practice: Study on the Molecular Mechanism of Traditional Chinese Medicine by Computational Pharmacology Methods: Part 1: Pharmacokinetic Modeling and Chemical Space Distribution
Letters in Drug Design & Discovery